Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus + tacrolimus versus tacrolimus + mycophenolate mofetil for regression of left ventricular hypertrophy in maintenance renal transplant recipients
2016-002198-37Phase 4Active
- Sponsor
- Bellvitge University Hospital
- Start
- Jul 2016
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in left ventricular hypertrophy (LVH) comparing Everolimus + tacrolimus with Tacrolimus + mycophenolate mofetil (2 arms). Primary endpoint: Left ventricular hypertrophy regression by cardiac MRI. Started Jul 2016; status: active.
02
Drugs
everolimustacrolimusmycophenolate mofetil
03
Conditions
left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on 2016-002198-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002198-37.